July 16 (Bloomberg) -- Amil Participacoes SA fell the most in a month after UBS AG cut its rating on the health insurance provider to “neutral” from “buy,” citing its price relative to earnings following a two-month rally.
Amil, the Rio de Janeiro-based insurer that agreed to buy Medial Saude SA last year, fell 3.7 percent to 14.45 reais in Sao Paulo trading at 5 p.m. close. The stock surged 20 percent through yesterday from its May 18 low.
“We believe that the stock is already pricing in most of the benefits from a successful turnaround at Medial,” Gustavo Piras Oliveira, an analyst at UBS, wrote in a note to clients.
Amil fetches 44 times reported earnings, compared with a price-to-earnings ratio of 13 for the Bovespa stock index, according to Bloomberg data.
UBS prefers OdontoPrev SA, Brazil’s largest provider of dental-care plans, over Amil, according to the report.
OdontoPrev, which trades at 32 times profits, dropped 1.3 percent to 16.30 reais today.
To contact the reporter on this story: Alexander Ragir in Rio de Janeiro at firstname.lastname@example.org.
To contact the editor responsible for this story: David Papadopoulos at email@example.com